US 8,084,035 B2 · CD38 modulated chemotaxis

Abstract

The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni.

Claims14

Dependent claims

An isolated SM38 polypeptide encoded by a nucleic acid molecule that binds over the full length to the complement nucleotide sequence of a nucleotide sequence that encodes:

(i) the SM38 amino acid sequence of FIG. 13A (SEQ ID NO:
5);
(ii) the SM38 amino acid sequence of FIG. 13A (SEQ ID NO:
5) having a deletion of one or more amino acids between 1-19;
(iii) the SM38 amino acid sequence of FIG. 13A (SEQ ID NO:
5) having a deletion of one or more amino acids between 276-303;
or
(iv) the SM38 amino acid sequence of FIG. 13A (SEQ ID NO:
5) having a deletion of one or more amino acids between 1-19 and 276-303
wherein said binding takes place in 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C.

7 more elements

Dependencies are inferred from the claim text.

CD38 modulated chemotaxis

Life of this patent

CD38 modulated chemotaxis

Life of this patent

Abstract

Claims14